Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Commission (EC) has approved KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination ...
Approval based on AZUR-1 data showing significant proportion of participants with no detectable signs of cancer one year or more after treatment ...
News Source: Ophelia Keating. (October 16, 2026). New Landmark-Guided Surgery Lets Scientists Inject Genes Into Multiple ...
Sun Pharmaceutical's Unloxcyt is recommended in cancer care guidelines as a significant treatment option for locally advanced ...
Nice to meet you. I run the "Anticancer Drug Encyclopedia."I am a practicing pharmacist and hold certifications and ...
Sun Pharma receives NCCN Category 2A Preferred designation for Unloxcyt in advanced CSCC: Our Bureau, Mumbai Wednesday, October 21, 2026, 13:15 Hrs [IST] Sun Pharmaceutical Indust ...
Colorectal cancer remains one of the world's most formidable health challenges, ranking as the second leading cause of cancer ...
FDA grants accelerated approval to GSK's Jemperli for stage II/III MSI-H or dMMR locally advanced rectal cancer. Read what this means for patients today.
The updated recommendation adds to the drug’s existing Category 2A designation for metastatic cutaneous squamous cell ...
UNLOXCYT receives NCCN Category 2A Preferred Designation for laCSCC patients ineligible for surgery or radiation. The ...
INTerpath-001 data to be presented in Presidential Symposium, featuring the first Phase 3 results for investigational intismeran autogene plus KEYTRUDA ® (pembrolizumab), demonstrating improvements in ...
The recommendation adds to UNLOXCYT’s Category 2A designation for metastatic cutaneous squamous cell carcinoma, assigned in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results